David Demanse
Impact in
Papers in
-
- Advanced Breast Cancer Therapies 4
- Oncology 6
- Cancer Treatment and Pharmacology 3
- Pancreatic and Hepatic Oncology Research 2
- Co-authors
- Jordi A. Rodon (8 shared papers)Howard A. Burris (6 shared papers)José Baselga (6 shared papers)Malte Peters (2 shared papers)Qinhua Cindy Ru (1 shared paper)Jaap Verweij (1 shared paper)Michael Goldbrunner (1 shared paper)Stefan S. De Buck (1 shared paper)
- Journals
- Annals of Oncology (4 papers)JAMA Oncology (2 papers)Journal of Clinical Oncology (2 papers)Journal of the European Academy of Dermatology and Venereology (1 paper)The Journal of Urology (1 paper)
- Partner nations
- SwitzerlandUnited StatesSpain
In The Last Decade
David Demanse
28 papers receiving 1.7k citations
David Demanse's Hit Papers
Peers
Comparison fields: 5 of 94
- Genetics 237
- Oncology 535
- Cancer Research 251
- Pulmonary and Respiratory Medicine 440
- Molecular Biology 958
Countries citing papers authored by David Demanse
This map shows the geographic impact of David Demanse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Demanse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Demanse more than expected).
Fields of papers citing papers by David Demanse
This network shows the impact of papers produced by David Demanse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Demanse. The network helps show where David Demanse may publish in the future.
Co-authors
The 25 scholars most cited alongside David Demanse, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 29 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors Hit paper breakdown → | 2011 | 611 |
| 2 | Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Hit paper breakdown → | 2018 | 353 |
| 3 | 2014 | 280 | |
| 4 | 2018 | 213 | |
| 5 | 2018 | 42 | |
| 6 | 2024 | 40 | |
| 7 | 2018 | 37 | |
| 8 | 2003 | 34 | |
| 9 | 2022 | 19 | |
| 10 | 2009 | 14 | |
| 11 | 2024 | 11 | |
| 12 | 2014 | 11 | |
| 13 | 2022 | 11 | |
| 14 | 2023 | 11 | |
| 15 | 2003 | 9 | |
| 16 | 2023 | 7 | |
| 17 | 2020 | 6 | |
| 18 | 2022 | 6 | |
| 19 | 2011 | 5 | |
| 20 | 2012 | 4 |
About David Demanse
David Demanse is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hepatology, Rheumatology and Molecular Biology, having authored 29 papers that have together received 1.7k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (6 papers), Advanced Breast Cancer Therapies (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Osteoarthritis Treatment and Mechanisms (3 papers), Cancer Treatment and Pharmacology (3 papers), Fibroblast Growth Factor Research (2 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Genetics (237 citations), Oncology (535 citations), Cancer Research (251 citations), Pulmonary and Respiratory Medicine (440 citations) and Molecular Biology (958 citations). David Demanse has collaborated with scholars based in Switzerland, United States and Spain. Frequent co-authors include Jordi A. Rodon, Howard A. Burris, José Baselga, Malte Peters, Qinhua Cindy Ru, Jaap Verweij, Michael Goldbrunner, Stefan S. De Buck, Diana C. Birle and Maja J.A. de Jonge. Their work appears in journals such as Annals of Oncology, JAMA Oncology, Journal of Clinical Oncology, Journal of the European Academy of Dermatology and Venereology and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.